S
Susan M. Domchek
Researcher at University of Pennsylvania
Publications - 501
Citations - 37655
Susan M. Domchek is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 83, co-authored 439 publications receiving 30495 citations. Previous affiliations of Susan M. Domchek include Brigham and Women's Hospital & Cancer Council Victoria.
Papers
More filters
Journal ArticleDOI
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Andrew Tutt,Mark E. Robson,Judy Garber,Susan M. Domchek,M. William Audeh,Jeffrey N. Weitzel,Michael Friedlander,Banu Arun,Niklas Loman,Rita K. Schmutzler,Andrew M Wardley,Gillian Mitchell,H. M. Earl,Mark Wickens,James Carmichael +14 more
TL;DR: Findings from this phase 2 study provide positive proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer.
Journal ArticleDOI
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark E. Robson,Seock-Ah Im,Elżbieta Senkus,Binghe Xu,Susan M. Domchek,Norikazu Masuda,Suzette Delaloge,Wei Li,Nadine Tung,Anne Armstrong,Wenting Wu,C. Goessl,Sarah Runswick,Pierfranco Conte +13 more
TL;DR: Among patients with HER2‐negative metastatic breast cancer and a germline BRCA mutation, Olaparib monotherapy provided a significant benefit over standard therapy; median progression‐free survival was 2.8 months longer and the risk of disease progression or death was 42% lower with olaparIB monotherapy than with standard therapy.
Journal ArticleDOI
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer
Andrew Tutt,Mark E. Robson,Judy Garber,Susan M. Domchek,M. W. Audeh,J. N. Weitzel,Michael Friedlander,B. K. Arun,Niklas Loman,Rita K. Schmutzler,Andrew M Wardley,Gillian Mitchell,H. M. Earl,Mark Wickens,J. Carmichael +14 more
TL;DR: The results of this study provide positive proof of concept for PARP inhibition in BRCA-deficient breast cancers and shows a favourable therapeutic index for a novel targeted treatment strategy in patients with tumours that have genetic loss of function of BRCa1-associated orBRCA2-associated DNA repair.
Journal ArticleDOI
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman,Ronnie Shapira-Frommer,Rita K. Schmutzler,M. William Audeh,Michael Friedlander,Judith Balmaña,Gillian Mitchell,Georgeta Fried,Salomon M. Stemmer,Ayala Hubert,Ora Rosengarten,Mariana Steiner,Niklas Loman,Karin Bowen,Anitra Fielding,Susan M. Domchek +15 more
TL;DR: Responses to olaparib were observed across different tumor types associated with germline BRCA1/2 mutations, and warrants further investigation in confirmatory studies.
Journal ArticleDOI
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
Susan M. Domchek,Tara M. Friebel,Christian F. Singer,D. Gareth Evans,Henry T. Lynch,Claudine Isaacs,Judy Garber,Susan L. Neuhausen,Ellen T. Matloff,Rosalind A. Eeles,Gabriella Pichert,Laura Van T'veer,Nadine Tung,Jeffrey N. Weitzel,Fergus J. Couch,Wendy S. Rubinstein,Wendy S. Rubinstein,Patricia A. Ganz,Mary B. Daly,Olufunmilayo I. Olopade,Gail E. Tomlinson,Joellen M. Schildkraut,Joanne L. Blum,Timothy R. Rebbeck +23 more
TL;DR: Among a cohort of women with BRCa1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower risk of breast cancer, first diagnosis of breastcancer, all-cause mortality, breast cancer-specific mortality, and ovarian cancer- specific mortality.